Figure 2.

The brief history of the development of drugs and current therapeutic strategies approved for mTNBC. mTNBC: metastatic triple-negative breast cancer; PARP: poly (ADP-ribose) polymerase; PD-L1: programmed death-ligand 1. (a) Single-agent chemotherapy is the preferred option, but combination regimens may be offered for symptomatic or immediately life-threatening disease (recommended by the European Society for Medical Oncology and American Society of Clinical Oncology). (b) Atezolizumab plus nab-paclitaxel was approved by the European Medicines Agency; pembrolizumab plus nab-paclitaxel and other chemotherapy was approved by the Food and Drug Administration. (c) There is insufficient evidence to determine the optimal sequencing of PARP inhibitors with other treatments. (d) Utidelone was approved by the National Medical Products Administration. Utidelone plus capecitabine was recommended by the Chinese Society of Clinical Oncology. (e) Food and Drug Administration and National Medical Products Administration approved.